Anzeige
Mehr »
Login
Sonntag, 19.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
GOLD-MINEN vor Jahrhundert-Hausse?! Diese Aktie sofort kaufen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
14 Leser
Artikel bewerten:
(0)

Over 340 life science executives converged on Santiago de Chile for Biolatam 2015 global life science partnering event Nov. 16-17

CARLSBAD, California and SANTIAGO, Chile, Nov. 23, 2015 /PRNewswire/ -- Biolatam® international life science partnering conference took place in Santiago, Chile, November 16-17 with great success. The event, produced by EBD Group and ASEBIO in collaboration with ProChile and Chile Biotech, was attended by over 340 life science dealmakers from pharma, biotech and service companies representing US, Latin American and European entities.

Biotech companies in attendance ranged in speciality area including health, biofuels, cosmetics, agrifood, and mining, and emerging medical technology companies. Also represented were established large medtech companies; venture capital, private equity, institutional firms and business angels; distributors and hospitals.

"We are pleased by the success of this second edition of Biolatam," said Anna Chrisman, Group Managing Director, EBD Group. "The energy was palpable, and innumerable connections were made to propel the market, both through partnering and through networking in the exhibition and evening event. Latin America is definitely a thriving emerging market that is only expected to grow."

"We have received many congratulations for this event, with a great interest of all participants, confirming the success of Biolatam as Latin America's leading biotechnology event," said Regina Revilla, Chair of ASEBIO.

Across Latin America, healthcare spending is projected to increase an average of 4.6 percent annually over 2014-2018, according to a recent Deloitte report, with pharmaceutical spending growth expected to rise an average of 6.1 percent annually. This is evidence of a growing emerging life science market, ripe for dealmaking with international companies who are actively seeking a presence in the region. Biolatam was created to foster these partnerships through dedicated one-to-one meetings facilitated by partneringONE® that could result in collaborations between companies that will fuel future growth.

The highly anticipated third edition of Biolatam will take place in San Juan, Puerto Rico, November 29-30, 2016.

Additional links and information:

Follow Biolatam 2015 on Twitter: @EBDGroup (hashtag: BLT15) and @BIOLATAM.

About EBD Group

EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group's partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.

EBD Group's conferences are run with the support of leading corporations and international trade associations and include:

  • BIO-Europe® and BIO-Europe Spring®, Europe's largest life science partnering conferences, supported by the Biotechnology Industry Organization (BIO)
  • BioPharm America', the fastest growing partnering event in North America
  • Biotech Showcase', a unique forum in San Francisco for presenting to investors and business development executives, co-produced with Demy-Colton Life Science Advisors
  • BioEquity Europe, the investor conference co-organized with BioCentury Publications and BIO
  • ChinaBio® Partnering Forum, the first dedicated biotech/pharma partnering conference in China, co-produced with ChinaBio® Group
  • Biolatam®, facilitating partnering among global life sciences executives in Latin America's vibrant life science hubs

EBD Group's sophisticated web-based partnering service, partneringONE®, is used as the partnering engine at numerous third-party events around the world, and partnering360® is the open online community of life science dealmakers that enhances partnering experiences throughout the year.

EBD Group is an Informa company. Informa is the largest publicly-owned organizer of exhibitions, conferences and training in the world.

EBD Group has offices in the USA and Europe.

For more information please visit www.ebdgroup.com.

About ASEBIO

The Spanish Bioindustry Association (ASEBIO), brings together 280 companies, associations, foundations, universities, research and technology centers that carry out activities directly or indirectly related to biotechnology in Spain.

Since 1999 ASEBIO has been acting as a meeting and promotion platform for those organizations interested in stimulating the national biotechnology scene.

In order to do this, ASEBIO works closely with regional, national and European governments as well as all the social organizations interested in using biotechnology to improve quality of life, the environment and generating skilled employment. ASEBIO, ranking fourth in Europe by number of members, is part of and supported by Europabio, the European Association for Bioindustries. ASEBIO is also the organizer of Biospain. (www.biospain2016.org).

For more information please visit: www.asebio.com

KI-Champions: 3 Top-Werte, die Ihr Portfolio revolutionieren
Fordern Sie jetzt den brandneuen kostenfreien Sonderreport an und erfahren Sie, wie Sie von den enormen Wachstumschancen im Bereich Künstliche Intelligenz profitieren können - 100 % kostenlos.
Hier klicken
© 2015 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.